AAAAI President Featured in USA Today “Asthma & Allergies” Supplement
AAAAI President, David B. Peden, MD, MS, FAAAAI, was featured in an article in the USA Today Supplement “Asthma & Allergies.” His foreword included information on the prevalence of allergic disease and emphasized the benefits of seeing a board certified allergist/immunologist. To view the article, click here.
AAAAI Fellow Leads Study Investigating Cancer Drug as Asthma Treatment
In a recent study in the New England Journal of Medicine (NEJM), lead investigator Elliot M. Israel, MD, FAAAAI, and his team looked into the possibility of using the cancer drug imatinib, commonly called Gleevec, as a possible treatment for severe refractory asthma. Patients on imatinib with severe asthma had decreased airway hyperresponsiveness, mast-cell counts and tryptase release compared to the placebo group. The study involved 62 patients. Half of the patients were treated with the drug and 8 of those patients dropped out. To learn more, read the article on STAT or view the article “KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma” on NEJM’s website.
- Latest Update on Venom Extract Shortage
- Flu Vaccine Still Recommended for Pregnant Women with Asthma
- What Do You Want to Ask the Future AAAAI President?
- Presenting the AAAAI Hypersensitivity Summer School
- Joint Congress Registration is Open to All Members. Do You Have Breaking Research to Submit?
- Sign Up for Webinars on MIPS and Quality Improvement
- Support Young A/I Researchers through the 2017 GAIN Campaign
- Renew Your AAAAI Membership Today to Continue Enjoying Your Member Benefits
- FITs: Submit Your Case Report for Inclusion at the Joint Congress
- Application Period for the ALA/AAAAI Allergic Respiratory Diseases Award Now Open
- Find the Next Step in Your Career